Hippo Pathway Drives Durable Non‐Cell‐Autonomous Ferroptosis Resistance in Lung Cancer
Cancer Science · 2026
DOI: 10.1111/cas.70299 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Mohamed Fathi Saleh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cellular Dynamics, Medical Research Laboratory, Institute of Integrated Research Institute of Science Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Ferroptosis, Lung Neoplasms, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medical Research Center Initiative for High Depth Omics, Kato Memorial Bioscience Foundation, Foundation for Promotion of Cancer Research in Japan.
Abstract (Originalsprache)
The Hippo pathway effector Yes‐associated protein (YAP) and transcriptional co‐activator with PDZ‐binding motif (TAZ) play a critical role in promoting lung cancer progression, but paradoxically increase tumor cell sensitivity to ferroptosis, a form of lipid peroxidation‐driven cell death. The mechanism through which YAP/TAZ‐high cells evade ferroptosis during cancer progression remains unclear. Here, we showed that YAP/TAZ‐low lung cancer cells confer durable ferroptosis resistance to neighboring YAP/TAZ‐high cells through a non‐cell‐autonomous mechanism. Using murine lung carcinoma cell coculture models, we demonstrated that transient exposure to YAP/TAZ‐deficient cells induces a stable, contact‐independent ferroptosis‐resistant state in wild‐type (WT) cells, enhancing their metastatic seeding capacity in vivo. This adaptation is mediated by the upregulation of Gch1 , which encodes GTP cyclohydrolase 1 and suppresses ferroptosis via the synthesis of the antioxidant metabolite tetrahydrobiopterin (BH4). GCH1 overexpression alone was sufficient to confer ferroptosis resistance in WT cells, whereas conditioned medium from YAP/TAZ‐deficient cells replicated this effect, indicating that a soluble factor is involved in Gch1 induction. Importantly, the genetic deletion of Gch1 in YAP/TAZ‐deficient cells abolished their ability to protect WT cells, confirming its essential role in this intercellular program. Our findings revealed a Hippo pathway‐linked ferroptosis resistance mechanism and suggested that intra‐tumoral heterogeneity in YAP/TAZ activity promotes metastatic fitness by enabling the survival of ferroptosis‐prone cells via antioxidant signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cellular Dynamics, Medical Research Laboratory, Institute of Integrated Research Institute of Science Tokyo, Tokyo, Japan.
- Department of Molecular and Medical Pharmacology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
ORCID-Profile: Toshiro Moroishi
Förderung
- Medical Research Center Initiative for High Depth Omics
- Kato Memorial Bioscience Foundation
- Foundation for Promotion of Cancer Research in Japan
- Princess Takamatsu Cancer Research Fund
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency
- Multilayered Stress Diseases
- Nanken-Kyoten
Zitieren
APA
Saleh, M. F., Nita, A., Ohta, Y., Kobayashi, A., Li, H., Sakamoto, Y., & Moroishi, T. (2026). Hippo Pathway Drives Durable Non‐Cell‐Autonomous Ferroptosis Resistance in Lung Cancer. Cancer Science. https://doi.org/10.1111/cas.70299
Vancouver
Saleh MF, Nita A, Ohta Y, Kobayashi A, Li H, Sakamoto Y, et al. Hippo Pathway Drives Durable Non‐Cell‐Autonomous Ferroptosis Resistance in Lung Cancer. Cancer Science. 2026. doi:10.1111/cas.70299
BibTeX
@article{Saleh2026,
author = {Saleh, Mohamed Fathi and Nita, Akihiro and Ohta, Yudai and Kobayashi, Aya and Li, Hao and Sakamoto, Yasuhisa and Moroishi, Toshiro},
title = {Hippo Pathway Drives Durable Non‐Cell‐Autonomous Ferroptosis Resistance in Lung Cancer},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70299}
}
EUVIMED